Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease

Yazdani, Armand N.; Pletsch, Michaela; Chorbajian, Abraham; Zitser, David; Rai, Vikrant; Agrawal, Devendra K.

doi:10.1080/14779072.2023.2264779

Cited by 9 publications

(1 citation statement)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, when BNP is elevated above age-and underlying diseasespecific thresholds, the potential for HF diagnosis increases accordingly. Moreover, because BNP is an effective predictor of death and acute cardiovascular events at 2-3 months (Yazdani et al, 2023), it can be used to assess cardiac function and longterm prognosis among patients with CHF. As an inflammatory Frontiers in Pharmacology frontiersin.org biomarker, hs-CRP is associated with worsening CHF pathogenesis (Magnussen and Blankenberg, 2018).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Shen Gui capsules for chronic heart failure: a systematic review and meta-analysis

Yan,

Zhang,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

BackgroundAlthough Shen Gui capsules (SGCP) are widely used as an adjuvant treatment for chronic heart failure (CHF), their clinical efficacy and safety remain controversial.PurposeTo assess the efficacy and safety of SGCP in the treatment of CHF through a systematic review and meta-analysis, to provide high-quality evidence for evidence-based medicine.MethodsSeven databases were searched for randomized controlled trials (RCTs) assessing SGCP for CHF, from inception to 9 January 2023. RCT quality of evidence was evaluated using the Cochrane Handbook for the Evaluation of Intervention Systems to assess risk of bias and Grading of Recommendations Assessment, Development, and Evaluation. A meta-analysis with subgroup and sensitivity analyses was performed using Review Manager 5.4 and Stata 12.ResultsNine RCTs representing 888 patients with CHF were included in the review. Meta-analysis revealed that SGCP combined with conventional heart failure therapy is more advantageous for improving left ventricular ejection fraction [LVEF; mean difference (MD) = 5.26, 95% confidence interval (CI) (3.78, 6.74), p < 0.0000] and increasing effective rate [relative risk (RR) = 1.21, 95%CI (1.14, 1.29), p < 0.001] compared with conventional therapy alone. The experimental treatment also reduced brain natriuretic peptide [MD = −100.15, 95%CI (−157.83, −42.47), p = 0.0007], left ventricular end-diastolic diameter [MD = −1.93, 95%CI (−3.22, −0.64), p = 0.003], and hypersensitive C-reactive protein [MD = −2.70, 95%CI (−3.12,−2.28), p < 0.001] compared with the control group. However, there was not a statistically significant difference in tumor necrosis factor-α [MD = −14.16, 95%CI (−34.04, 5.73), p = 0.16] or left ventricular end-systolic diameter [MD = −1.56, 95%CI (−3.13, 0.01), p = 0.05]. Nor was there a statistically significant between-groups difference in incidence of adverse events (p > 0.05).ConclusionSGCP combined with conventional heart failure therapy can improve LVEF and increase the effective rate to safely treat patients with CHF. However, further high-quality studies are needed to confirm these findings, due to the overall low quality of evidence in this literature.Clinical Trial Registration:https://www.crd.york.ac.uk/PROSPERO/logout.php, PROSPERO [CRD42023390409].

show abstract

Section: Discussionmentioning

confidence: 99%